Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company (BMY)

Market Closed
23 Jul, 20:00
NYSE NYSE
$
61. 51
+0.75
+1.2344%
$
122.85B Market Cap
- P/E Ratio
2.52% Div Yield
7.6M Volume
- Eps
$ 60.76
Previous Close
Add Transaction
Day Range
60.45 62.04
Year Range
42.52 62.89
Want to track BMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Top Dividend Stocks To Buy In July 2024? 2 In Focus

Top Dividend Stocks To Buy In July 2024? 2 In Focus

Dividend stocks for your July 2024 watchlist.

Stockmarket | 2 years ago
3 Defensive Stocks to Buy During the Market Dip

3 Defensive Stocks to Buy During the Market Dip

Despite markets reaching new heights recently, many defensive stocks with reliable and consistent demand are still experiencing their own market dip. They have pulled back as investors repositioned into the artificial intelligence (AI) trend.

Investorplace | 2 years ago
Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

247wallst | 2 years ago
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges

Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges

Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday.

Reuters | 2 years ago
Buy The Drop On These 6% Dividend Value Picks

Buy The Drop On These 6% Dividend Value Picks

AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices, high dividend yields, and potential for market-beating returns. W.P. Carey yields 6.3% and offers growth potential through European property acquisitions, while Bristol Myers Squibb gives a 5.6% yield and has growth prospects driven by a strong drug pipeline.

Seekingalpha | 2 years ago
Is Bristol Myers Squibb Stock a Buy?

Is Bristol Myers Squibb Stock a Buy?

Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs.

Fool | 2 years ago
5 Stocks I Sold Due To "Fragile Stagflation" Risk

5 Stocks I Sold Due To "Fragile Stagflation" Risk

Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, why I sold them, my barbell strategy, and how much cash I am holding in my investment portfolios.

Seekingalpha | 2 years ago
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.

You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.

The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.

Investorplace | 2 years ago
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 2 years ago
Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?

Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?

Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this period.

Forbes | 2 years ago
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.

Zacks | 2 years ago
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Zacks | 2 years ago
Loading...
Load More